A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors — Stella
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
United States
City Of Hope Comprehensive Cancer Center /ID# 276550, Duarte, California
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278432, Irvine, California
START Midwest /ID# 272505, Grand Rapids, Michigan
Carolina BioOncology Institute /ID# 272380, Huntersville, North Carolina
Next Oncology - Irving /ID# 276659, Irving, Texas
Israel
The Chaim Sheba Medical Center /ID# 276798, Ramat Gan, Tel Aviv
Rambam Health Care Campus- Haifa /ID# 276799, Haifa
Hadassah Medical Center-Hebrew University /ID# 276800, Jerusalem
Japan
Kansai Medical University Hospital /ID# 276586, Hirakata-shi, Osaka